Celltrion Receives Health Canada's Approval for Remsima SC (biosimilar- infliximab) for Rheumatoid Arthritis
Shots:
- The Health Canada has granted a NOC which is based on clinical evidence for Remsima/CT-P13 SC vs CT-P13 IV up to 1year in patients with RA. The results demonstrated that switching patients from Remsima IV to its SC formulation @30wks. is comparable to maintaining Remsima SC up to 54wks.
- The therapy has shown similar efficacy and safety profile of CT-P13 IV and provides patients an opportunity of self-administration to control their own treatment
- The company applied patent protection until 2038 for Remsima SC in ~ 100 countries throughout North America- EU and Asia and will be the first product to enter the Canadian market
Ref: Newswire Canada | Image: Celltrion
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com